Good afternoon, my name is Larry Greenhill, M.D., and I am President-elect of the American Academy of Child and Adolescent Psychiatry. Over the past 24 months, I have received research support or have worked on a consultant basis with Otsuka, Johnson & Johnson, Forest, Pfizer, and NIMH. I have both practiced child psychiatry, been federally supported to study long-term adverse events associated with psychotropic medication use, and been a member of AACAP for 30 years. AACAP is a professional medical association of 8,000 child and adolescent psychiatrists established in 1953. AACAP is the leading national medical association dedicated to treating and improving the quality of life for the estimated 7 - 12 million American youth under 18 years of age who are affected by emotional, behavioral, developmental and mental disorders.

Bipolar and Schizophrenia are severe psychiatric illnesses which first appear in childhood and adolescence. No one treatment option works for all children and adolescents with these disorders so we support a wide array of treatment options being available. Although a few clinical trials have suggested that these antipsychotic medications can be effective in pediatric populations, the lack of systematically collected safety data when youth are exposed for long periods of time, that may affect development strongly, indicates that large scale Phase IV studies need to be carried out.

We ask the FDA Advisory Committee to carefully consider whether the number and scope of the clinical trials as well as the duration of the safety trials to date involving children and adolescents justifies the labeling changes being requested today. While these medications may be helpful and even life saving for some children and adolescents suffering with these disorders, there are significant metabolic and cardiac adverse events associated with their use. We advise the FDA not to approve the request for indications in these medications unless they are also requiring that children treated be entered into a registry. These registries can take advantage of large group-practice HMO settings where electronic health records and pharmacological prescription data can be aggregated and compared. The resulting systematically collected information on the risks and benefits of these medications as well as specific methods for effective monitoring of their associated side effects must be made available to the public before direct-to-consumer marketing should be permitted to occur.

We thank the FDA for the opportunity for the American Academy of Child and Adolescent Psychiatry to provide this testimony.